<DOC>
	<DOCNO>NCT02382068</DOCNO>
	<brief_summary>This randomize pilot clinical trial study dexamethasone prevent hearing loss patient receive cisplatin . Injecting steroid , dexamethasone , behind eardrum chemotherapy may help protect cisplatin-associated hearing loss .</brief_summary>
	<brief_title>Dexamethasone Preventing Hearing Loss Patients Receiving Cisplatin</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Investigate potential protective effect intratympanic dexamethasone administration cisplatin-induced ototoxicity . OUTLINE : Patients randomize ear receives dexamethasone . Patients receive dexamethasone via intratympanic injection one ear placebo via intratympanic injection ear . After completion study treatment , patient follow cisplatin treatment 1 3 month last cisplatin treatment .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Planned cisplatin treatment restrict follow treatment course criterion : Dose : &gt; 50 mg/m^2 Frequency : every ( q ) 3q4 week Cycles : 7 maximum Previous cisplatin treatment Previous concurrent radiation treatment head neck region Previous exist pathology external middle ear would preclude auditory test and/or intratympanic dexamethasone delivery Previous exist pathology inner ear without hear loss ( i.e . sudden sensorineural hearing loss , Meniere 's disease , autoimmune inner ear disease ) Previous exist pathology central nervous system potential impact auditory pathway ( i.e . major head trauma , meningitis , encephalitis , brain metastasis , vestibular schwannoma ) Recent steroid treatment within last month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>